Literature DB >> 20430759

Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Md Jashim Uddin1, Brenda C Crews, Anna L Blobaum, Philip J Kingsley, D Lee Gorden, J Oliver McIntyre, Lynn M Matrisian, Kotha Subbaramaiah, Andrew J Dannenberg, David W Piston, Lawrence J Marnett.   

Abstract

Effective diagnosis of inflammation and cancer by molecular imaging is challenging because of interference from nonselective accumulation of the contrast agents in normal tissues. Here, we report a series of novel fluorescence imaging agents that efficiently target cyclooxygenase-2 (COX-2), which is normally absent from cells, but is found at high levels in inflammatory lesions and in many premalignant and malignant tumors. After either i.p. or i.v. injection, these reagents become highly enriched in inflamed or tumor tissue compared with normal tissue and this accumulation provides sufficient signal for in vivo fluorescence imaging. Further, we show that only the intact parent compound is found in the region of interest. COX-2-specific delivery was unambiguously confirmed using animals bearing targeted deletions of COX-2 and by blocking the COX-2 active site with high-affinity inhibitors in both in vitro and in vivo models. Because of their high specificity, contrast, and detectability, these fluorocoxibs are ideal candidates for detection of inflammatory lesions or early-stage COX-2-expressing human cancers, such as those in the esophagus, oropharynx, and colon. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430759      PMCID: PMC2864539          DOI: 10.1158/0008-5472.CAN-09-2664

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Cyclooxygenase enzymes: catalysis and inhibition.

Authors:  R G Kurumbail; J R Kiefer; L J Marnett
Journal:  Curr Opin Struct Biol       Date:  2001-12       Impact factor: 6.809

2.  Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.

Authors:  A S Kalgutkar; B C Crews; S W Rowlinson; A B Marnett; K R Kozak; R P Remmel; L J Marnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform.

Authors:  J E Bugaj; S Achilefu; R B Dorshow; R Rajagopalan
Journal:  J Biomed Opt       Date:  2001-04       Impact factor: 3.170

4.  The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.

Authors:  R F Jacoby; K Seibert; C E Cole; G Kelloff; R A Lubet
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

5.  Cyclooxygenase-2 expression in Barrett's esophagus.

Authors:  H M Kandil; G Tanner; W Smalley; S Halter; A Radhika; R N Dubois
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

Review 6.  The COXIB experience: a look in the rearview mirror.

Authors:  Lawrence J Marnett
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

7.  Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation.

Authors:  Erik F J de Vries; Janine Doorduin; Rudi A Dierckx; Aren van Waarde
Journal:  Nucl Med Biol       Date:  2007-09-19       Impact factor: 2.408

8.  Isoform-selective interaction of cyclooxygenase-2 with indomethacin amides studied by real-time fluorescence, inhibition kinetics, and site-directed mutagenesis.

Authors:  Sergei L Timofeevski; Jeffery J Prusakiewicz; Carol A Rouzer; Lawrence J Marnett
Journal:  Biochemistry       Date:  2002-07-30       Impact factor: 3.162

Review 9.  Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments.

Authors:  Kazuhito Tanabe; Zhouen Zhang; Takeo Ito; Hiroshi Hatta; Sei-ichi Nishimoto
Journal:  Org Biomol Chem       Date:  2007-10-01       Impact factor: 3.876

10.  Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor.

Authors:  Frank Wuest; Torsten Kniess; Ralf Bergmann; Jens Pietzsch
Journal:  Bioorg Med Chem       Date:  2008-07-10       Impact factor: 3.641

View more
  62 in total

Review 1.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

2.  A Raman-based endoscopic strategy for multiplexed molecular imaging.

Authors:  Cristina L Zavaleta; Ellis Garai; Jonathan T C Liu; Steven Sensarn; Michael J Mandella; Dominique Van de Sompel; Shai Friedland; Jacques Van Dam; Christopher H Contag; Sanjiv S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-23       Impact factor: 11.205

3.  An Activity-Based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells.

Authors:  Anuj K Yadav; Christopher J Reinhardt; Andres S Arango; Hannah C Huff; Liang Dong; Michael G Malkowski; Aditi Das; Emad Tajkhorshid; Jefferson Chan
Journal:  Angew Chem Int Ed Engl       Date:  2020-02-06       Impact factor: 15.336

4.  Targeted imaging of cancer by fluorocoxib C, a near-infrared cyclooxygenase-2 probe.

Authors:  Md Jashim Uddin; Brenda C Crews; Kebreab Ghebreselasie; Cristina K Daniel; Philip J Kingsley; Shu Xu; Lawrence J Marnett
Journal:  J Biomed Opt       Date:  2015-05       Impact factor: 3.170

5.  Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Menyhárt B Sárosi; Cristina M Daniel; Kebreab Ghebreselasie; Matthias S Scholz; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-10-15       Impact factor: 3.466

6.  Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.

Authors:  Md Jashim Uddin; Brenda C Crews; Shu Xu; Kebreab Ghebreselasie; Cristina K Daniel; Philip J Kingsley; Surajit Banerjee; Lawrence J Marnett
Journal:  ACS Chem Biol       Date:  2016-09-19       Impact factor: 5.100

7.  (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2.

Authors:  Kelsey C Duggan; Daniel J Hermanson; Joel Musee; Jeffery J Prusakiewicz; Jami L Scheib; Bruce D Carter; Surajit Banerjee; J A Oates; Lawrence J Marnett
Journal:  Nat Chem Biol       Date:  2011-11       Impact factor: 15.040

8.  Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-05-06       Impact factor: 3.466

9.  Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization.

Authors:  Md Jashim Uddin; Chauca E Moore; Brenda C Crews; Cristina K Daniel; Kebreab Ghebreselasie; J Oliver McIntyre; Lawrence J Marnett; Ashwath Jayagopal
Journal:  J Biomed Opt       Date:  2016-09-01       Impact factor: 3.170

10.  Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo.

Authors:  Maria Cekanova; Md Jashim Uddin; Joseph W Bartges; Amanda Callens; Alfred M Legendre; Kusum Rathore; Laura Wright; Amanda Carter; Lawrence J Marnett
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.